Stocks › RGC
Regencell Bioscience Holdings Ltd
RGC·Nasdaq·USD
$7.35
+0.11 (+1.52%)
Close · Oct 6, 2026 · Close Prices from Tiingo.com
RGC
Regencell Bioscience Holdings Ltd · Nasdaq
Nasdaq 100S&P 500
Filings
Default90D1Y5YALL
RGCS&P 500 (rebased)
Congress BuyCongress SellInsider BuyInsider SellForm 1448-K ResultsLobbying
Loading price history…
Daily closes, adjusted for splits and dividends · Close Prices from Tiingo.comHover a marker, every one is a filing · move across the line for the crosshair
Congressional Trades
Recent trades of RGC by members of U.S. Congress · 13 on record
Whale Activity
Institutional 13F positions
No 13F positions in RGC among the institutional filers we track.
KeyVex tracks a curated set of large 13F filers plus the largest positions in recent filings, so this is a sample of institutional activity, not the whole market.
Insider Trading
Net shares bought (+) or sold (−) on the open market by RGC insiders, by quarter · Form 4
No open-market insider buys or sells in the last two years.
Recent Insider Transactions
1,106 transactions on record · newest first
| Insider | Type | Shares | Price | Value | Date | |
|---|---|---|---|---|---|---|
| CAMPBELL MICHAEL LDirector | Disposition to issuer | −703.7K | $23.00 | $16.2M | Feb 28, 2018 | Form 4 ↗ |
| YEMENIDJIAN ALEXDirector | Disposition to issuer | −21.9K | $23.00 | $503K | Feb 28, 2018 | Form 4 ↗ |
| TYRRELL JACKDirector | Disposition to issuer | −136.7K | $23.00 | $3.1M | Feb 28, 2018 | Form 4 ↗ |
| TYRRELL JACKDirector | Disposition to issuer | −100.0K | $23.00 | $2.3M | Feb 28, 2018 | Form 4 ↗ |
| TYRRELL JACKDirector | Disposition to issuer | −33.1K | $23.00 | $761K | Feb 28, 2018 | Form 4 ↗ |
| TYRRELL JACKDirector | Disposition to issuer | −10.4K | $23.00 | $240K | Feb 28, 2018 | Form 4 ↗ |
| THOMAS LEE MDirector | Disposition to issuer | −46.6K | $23.00 | $1.1M | Feb 28, 2018 | Form 4 ↗ |
| THOMAS LEE MDirector | Disposition to issuer | −33.2K | $23.00 | $763K | Feb 28, 2018 | Form 4 ↗ |
| THOMAS LEE MDirector | Disposition to issuer | −10.4K | $23.00 | $240K | Feb 28, 2018 | Form 4 ↗ |
| KEYTE DAVID HDirector | Disposition to issuer | −5,767 | $23.00 | $133K | Feb 28, 2018 | Form 4 ↗ |
| KEYTE DAVID HDirector | Disposition to issuer | −5,767 | $23.00 | $133K | Feb 28, 2018 | Form 4 ↗ |
| KEYTE DAVID HDirector | Disposition to issuer | −73.6K | $23.00 | $1.7M | Feb 28, 2018 | Form 4 ↗ |
| KAPLAN STEPHEN ADirector | Disposition to issuer | −161.0K | $23.00 | $3.7M | Feb 28, 2018 | Form 4 ↗ |
| Brymer Charles EDirector | Disposition to issuer | −75.8K | $23.00 | $1.7M | Feb 28, 2018 | Form 4 ↗ |
| BELL THOMAS D JRDirector | Disposition to issuer | −132.4K | $23.00 | $3.0M | Feb 28, 2018 | Form 4 ↗ |
| BRANDOW PETER BEVP, General Counsel, Sec. | Disposition to issuer | −236.5K | $23.00 | $5.4M | Feb 28, 2018 | Form 4 ↗ |
| Ownby DavidEVP, CFO and Treasurer | Disposition to issuer | −256.8K | $23.00 | $5.9M | Feb 28, 2018 | Form 4 ↗ |
| DUNN GREGORY WPresident and COO | Disposition to issuer | −98.4K | $23.00 | $2.3M | Feb 28, 2018 | Form 4 ↗ |
| MILES AMY EChief Executive Officer · Director | Disposition to issuer | −740.8K | $23.00 | $17.0M | Feb 28, 2018 | Form 4 ↗ |
| ANSCHUTZ PHILIP F10% owner | Disposition to issuer | −23.7M | — | — | Feb 28, 2018 | Form 4 ↗ |
Fund Holders
Mutual funds and ETFs holding RGC · SEC Form N-PORT
Funds report their holdings by CUSIP, and RGC could not be matched to one, so no fund holdings are shown.
Activist & Passive Stakes
Schedule 13D / 13G beneficial-ownership filings
No 13D/13G beneficial-ownership filings on record.
Corporate Lobbying
Estimated quarterly lobbying spending reported under the LDA, filings naming Regencell Bioscience Holdings Ltd as client
No lobbying filings found naming Regencell Bioscience Holdings Ltd as the client.
Government Contracts
Federal awards to Regencell Bioscience Holdings Ltd · USAspending
No federal contract awards found for Regencell Bioscience Holdings Ltd.
U.S. Patents
Recent USPTO applications naming Regencell Bioscience Holdings Ltd
No USPTO patent applications found for Regencell Bioscience Holdings Ltd.
Annual Financials
From RGC's 10-K filings · XBRL
No annual XBRL figures on record for RGC. KeyVex's fundamentals cover about 130 large companies so far.
Stock Splits
Every split and reverse split in the price history
- 38-for-1Stock splitJun 16, 2025
Split dates and ratios from the price history · Close Prices from Tiingo.com
Material Events (8-K)
Corporate events filed with the SEC
No 8-K filings on record.
About Regencell Bioscience Holdings Ltd
From SEC EDGAR company records
Industry (SIC 2833)Medicinal Chemicals & Botanical Products
SectorHealthcare
HeadquartersHONG KONG
IncorporatedE9
SEC CIK0001829667 ↗